Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.32 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.32 |
| ▸ | TXNRD1 | Q16881 | 5/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3768551 | 0.85 | MAPT (0.42) | NPSR1HTTGSTP1GSTM2TXNRD1 | |
| SCHEMBL27138016 | 0.80 | TXNRD1 (0.35) | NPSR1TXNRD1MAPTLMNA | |
| SCHEMBL3776749 | 0.80 | PAX8 (0.35) | NPSR1ALDH1A1HTTGSTP1GSTM2 | |
| SCHEMBL31052537 | 0.79 | BACE1 (0.36) | BACE1LMNASSTR4 | |
| SCHEMBL31052536 | 0.79 | BACE1 (0.36) | BACE1LMNASSTR4 | |
| SCHEMBL24549805 | 0.79 | KCNH2 (0.33) | NPSR1ALDH1A1HTTMAPTLMNA | |
| SCHEMBL24549830 | 0.79 | BACE1 (0.35) | BACE1NPSR1ALDH1A1HTTMAPT | |
| SCHEMBL22504098 | 0.78 | KMT2A (0.41) | NPSR1ALDH1A1TXNRD1MAPTRAB9A | |
| SCHEMBL31052514 | 0.78 | BACE1 (0.37) | BACE1NPC1RAB9ALMNASSTR4 | |
| SCHEMBL31719744 | 0.77 | L3MBTL1 (0.34) | HTTKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | BACE1 2544/4885NPSR1 4298/4885ALDH1A1 4544/4885 |
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | BACE1 2689/4885NPSR1 4243/4885ALDH1A1 4541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.